Liu Z Y, Cui Q, Liu G T
Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing.
Yao Xue Xue Bao. 1996;31(2):101-6.
DDB is a hepatoprotectant and has been widely used for the treatment of chronic viral hepatitis in China. The drug markedly improved the abnormal liver function particularly in lowering the elevated serum transaminases in patients. It is known that there is a close correlation between primary hepatocarcinoma and chronic viral hepatitis. The aim of the present study is to evaluate the effect of DDB on hepatocarcinoma cell line. The results showed that the growth and clonogenicity of Bel-7402 human hepatocarcinoma cell line cultured with DDB were markedly inhibited. The nucleoles of the cells treated with DDB disappeared or their numbers and nucleus/cytoplasm ratio decreased under electron microscopic observation. DDB at the concentration of 10(-4) mol.L-1 significantly increased the contents of cAMP and calmodulin (CaM) in Bel-7402 hepatocarcinoma cells. DDB was also found to inhibit topoisomerase II activity of Bel-7402 hepatocarcinoma cells. These results suggest that the mechanism of inhibition of DDB on several phenotypes of Bel-7402 cell line may be related to its effect on cAMP and CaM content as well as topoisomerase II activity.
联苯双酯是一种保肝药，在中国已被广泛用于治疗慢性病毒性肝炎。该药物能显著改善肝功能异常，尤其能降低患者升高的血清转氨酶。众所周知，原发性肝癌与慢性病毒性肝炎之间存在密切关联。本研究的目的是评估联苯双酯对肝癌细胞系的作用。结果显示，用联苯双酯培养的Bel-7402人肝癌细胞系的生长和克隆形成能力受到显著抑制。在电子显微镜观察下，用联苯双酯处理的细胞的核仁消失，或者其数量及核质比降低。浓度为10(-4) mol.L-1的联苯双酯显著增加了Bel-7402肝癌细胞中cAMP和钙调蛋白（CaM）的含量。还发现联苯双酯能抑制Bel-7402肝癌细胞的拓扑异构酶II活性。这些结果表明，联苯双酯对Bel-7402细胞系几种表型的抑制机制可能与其对cAMP和CaM含量以及拓扑异构酶II活性的影响有关。
